Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 5:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Positive Choice Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus

NCT01353040
View directory record Official record
Conditions
Marburg Hemorrhagic Fever
Interventions
AVI-6003, Placebo
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 6, 2012 · Synced Sep 12, 2026, 5:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Affect-based, Self-selected, and Traditional Exercise Prescriptions

NCT03047590
View directory record Official record
Conditions
Physical Activity
Interventions
Choice-based Exercise Intensity, Positive Affect Focus, Heart rate-based Exercise Intensity
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Sep 12, 2026, 5:55 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

NCT04975308
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
48
States / cities
Chandler, Arizona • Gilbert, Arizona • Greenbrae, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 12, 2026, 5:55 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions

NCT04905160
View directory record Official record
Conditions
Heart Failure, ADHF, Acute MI
Interventions
COMPASSION Digital Biomarker
Other
Lead sponsor
Aventyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 12, 2026, 5:55 PM EDT
Completed Not applicable Interventional

Optimizing Resilience and Coping in HIV Via Internet Delivery

NCT01997008
View directory record Official record
Conditions
HIV Disease, Depression, Affect, Psychological Stress
Interventions
Intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Sep 12, 2026, 5:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Online Single-Session Interventions on College Student Well-being

NCT04287374
View directory record Official record
Conditions
Well-Being, Depressive Symptoms, Anxiety, Affect
Interventions
Multi-component Well-being Intervention, Study Skills
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 22 Years
Enrollment
294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Cambridge, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 12, 2026, 5:55 PM EDT
Completed Phase 3 Interventional Results available

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

NCT01419197
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab emtansine, Treatment of physician's choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
59
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Hayward, California + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Sep 12, 2026, 5:55 PM EDT
Terminated Phase 4 Interventional

Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy

NCT00234962
View directory record Official record
Conditions
HIV Infection
Interventions
Lopinavir/Ritonavir
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2008 · Synced Sep 12, 2026, 5:55 PM EDT
Terminated Phase 4 Interventional Results available

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

NCT04031885
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abemaciclib, Fulvestrant, Standard Chemotherapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
55
States / cities
Avondale, Arizona • Phoenix, Arizona • Yuma, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Sep 12, 2026, 5:55 PM EDT
Completed Not applicable Interventional Results available

Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project

NCT03799341
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Prize-Based Contingency Management, Treatment As Usual Outpatient Substance Use Treatment
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 12, 2026, 5:55 PM EDT
Recruiting Phase 3 Interventional

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

NCT06435429
View directory record Official record
Conditions
Metastatic HER2-positive Breast Cancer
Interventions
Zanidatamab, Trastuzumab, Eribulin, Vinorelbine, Gemcitabine, Capecitabine
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
48
States / cities
Phoenix, Arizona • Tucson, Arizona • Cerritos, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 12, 2026, 5:55 PM EDT
Recruiting Phase 2 Interventional

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

NCT07288034
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Bevacizumab, Biopsy Procedure, Biospecimen Collection, Chemotherapy, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Monitoring, Positron Emission Tomography, Surveillance, Tremelimumab
Drug · Biological · Procedure + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
13
States / cities
Goodyear, Arizona • Corona, California • Duarte, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 12, 2026, 5:55 PM EDT
Terminated Phase 1 Interventional

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

NCT02476955
View directory record Official record
Conditions
Solid Tumors, Ovarian Cancer, Endometrial Cancer
Interventions
ARQ 092 + carboplatin + paclitaxel (Closed), ARQ 092 + paclitaxel (Closed), ARQ 092 + anastrozole
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Sep 12, 2026, 5:55 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

A Stepped Care Approach to Treating Tobacco Use in Rural Veterans

NCT04501016
View directory record Official record
Conditions
Tobacco Cessation
Interventions
Tailored behavioral counseling, Tobacco cessation pharmacotherapy
Behavioral · Drug
Lead sponsor
Iowa City Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 12, 2026, 5:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

NCT03280563
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody, Bevacizumab, Entinostat, Exemestane, Fulvestrant, Ipatasertib, Tamoxifen, Abemaciclib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 12, 2026, 5:55 PM EDT
Completed Phase 2 Interventional Results available

De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study

NCT02281955
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions
Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation
Radiation · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
5
States / cities
Gainesville, Florida • Chapel Hill, North Carolina • Hendersonville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 12, 2026, 5:55 PM EDT
Completed Not applicable Interventional

Functional Precision Oncology for Metastatic Breast Cancer

NCT04450706
View directory record Official record
Conditions
HER2-negative Breast Cancer
Interventions
Precision Medicine, Physican Decision Making
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 27, 2024 · Synced Sep 12, 2026, 5:55 PM EDT
Completed No phase listed Observational

A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations

NCT03955913
View directory record Official record
Conditions
Urothelial Cancer, Receptors, Fibroblast Growth Factor
Interventions
Archival Tumor Tissue Sample
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
3,679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Tucson, Arizona • Denver, Colorado • Newark, Delaware + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 12, 2026, 5:55 PM EDT
Recruiting Not applicable Interventional

Implementing a Contingency Management Program Addressing Methamphetamine Use For and With the People of Hawaii

NCT06532370
View directory record Official record
Conditions
Contingency Managment, Methamphetamine Use Disorder
Interventions
Contingency Managment
Behavioral
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 12, 2026, 5:55 PM EDT
Not yet recruiting Early Phase 1 Interventional

Individualized fMRI-guided TMS for Depression

NCT07804459
View directory record Official record
Conditions
Depression, Major Depressive Disorder (MDD), Depression - Major Depressive Disorder, Persistent Depressive Disorder, PDD, MDD
Interventions
Active Repetitive Transcranial Magnetic Stimulation (rTMS), Sham Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 12, 2026, 5:55 PM EDT
Recruiting Phase 2 Interventional

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

NCT05467891
View directory record Official record
Conditions
Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Interventions
Ribociclib, Fulvestrant, Anastrozole, Letrozole, Exemestane
Drug
Lead sponsor
Oana Danciu
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 12, 2026, 5:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

C2P Mobilization Intervention (Pilot)

NCT00393575
View directory record Official record
Conditions
HIV Infections
Interventions
Community Mobilization
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
14
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 12, 2026, 5:55 PM EDT
Recruiting Phase 3 Interventional

Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT 2

NCT04678154
View directory record Official record
Conditions
Post Operative Surgical Site Infection
Interventions
Standard of care, Vancomycin and Tobramycin
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
31
States / cities
Redwood City, California • San Francisco, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 12, 2026, 5:55 PM EDT
Completed Not applicable Interventional Results available

Improving Outcomes for Low-Income Mothers With Depression

NCT03221556
View directory record Official record
Conditions
Post Partum Depression
Interventions
Engagement-Focused Care Coordination (EFCC), Problem Solving Education (PSE)
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 12, 2026, 5:55 PM EDT